Pharmaceutical Litigation Attorneys
WE ARE NO LONGER ACCEPTING PROPECIA CASES
Hair loss is a common occurrence, most often experienced by men as they age. To combat hair loss and baldness, Propecia (finasteride) for men prevents the conversion of testosterone to dihydrotestosterone. Manufactured by the pharmaceutical giant Merck & Co., Propecia was immediately a hit amongst balding men upon its release. However, Propecia can result in
adverse sexual and health side effects for patients, and can be dangerous for women and children who are exposed to the drug.
Side Effects of Propecia
The adverse side effects of Propecia for men are many. These include:
- Decreased libido;
- Erectile dysfunction;
- Depressive symptoms; and
- Suicidal thoughts;
- Increased risk of prostate cancer; and
- Increased risk of breast cancer.
The above risks are not the only ones associated with the drug; Propecia can also be dangerous for women and children who are exposed to it. In fact, there is evidence to suggest that
Propecia may cause birth defects in the fetus of a woman who is exposed to Propecia during pregnancy.
While Merck & Co. published some of these risks when Propecia was released, other risks were not made known. Furthermore, the fact that certain side effects could continue even when a person stopped taking Propecia was not published.
Filing a Lawsuit against Merck & Co.
Because Merck & Co. did not fully disclose the dangers associated with taking or being exposed to Propecia, the drug manufacturing company violated its duty of care to the consumer. As such, the company may be held liable for all harm that a patient experiences as a direct result of taking the drug. If you have suffered adverse effects due to taking Propecia, you may have a cause of action against Merck & Co.
Consult with a Pharmaceutical Litigation Attorney Today
A consultation with the experienced
pharmaceutical litigation attorneys at Napoli Shkolnik, PLLC can help you recover damages for the harm that you have suffered. To learn more, contact our team today by
calling our offices at your earliest convenience.
1월 28, 2026
by Christopher R. LoPalo, Partner AstraZeneca has withdrawn Andexxa (andexanet alfa) from the United States market effective December 22, 2025. Patients who experienced adverse health outcomes, complications, or...
Read the Article
1월 21, 2026
For PFAS in biosolids, 2025 was the year statehouses stepped decisively into the vacuum. While federal policy is evolving, state and local governments are rapidly redrawing the rules...
Read the Article
1월 14, 2026
Bringing a baby into the world is supposed to be joyful. When something goes wrong during pregnancy, labor, or delivery, that joy can be replaced in an instant...
Read the Article